A drug called teprotumumab helps people with thyroid eye disease by reducing swelling, pain, and other symptoms — and it's already approved by health regulators.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease

Narrative Review

2020 Dec

The study says that teprotumumab works for thyroid eye disease and is already approved, which matches the claim.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease

Score: 1

DOI: 10.1159/000511538

Similar Assertions

Using two treatments together—one for the TSH receptor and one for the IGF-1 receptor—might work better and cause fewer side effects for people with thyroid eye disease than using just one of them alone.

1

0

75%

Some new treatments for thyroid eye disease might work better by hitting two different pathways in the eye that cause swelling, instead of just one.

1

0

73%